Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
The clinical ambitions of these two ASX biotechs just got a boost from the FDA
News
10 at 10: These ASX stocks are running wild this morning
Health & Biotech
‘Miracle’ breakthrough in melanoma fight puts focus on ASX stocks in the skin cancer space
News
Market highlights and 5 ASX small caps to watch on Tuesday
News
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention
Health & Biotech
Invion led a group of ASX cancer stocks up after promising news
Experts
ScoPo’s Powerplays: Hearing tech, medical devices to ride out choppy market
News
Last Orders: ASX 200 rebounds, but the IT sector slumps 10 per cent for the week
Health & Biotech
Immutep up 11pc on US fast-track designation for lead drug candidate
News
Market highlights and 4 ASX small caps to watch on Thursday
Health & Biotech
Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents
News
Market highlights and 5 ASX small caps to watch on Wednesday
Experts
ScoPo’s powerplays: His Mach7 pick paid off – will Impedimed rise as well?
News
Last Rounds: Small caps finally get some love, rise 1.2%
Health & Biotech
Immutep shares soar after Bristol Myers Squibb study confirms LAG-3 potency
Health & Biotech
